BCIQ Profiles

Company Profile Report

June 26 Company Quick Takes: Dupixent approved for nasal polyps; plus Ono/Rafael, Oxford/Santen and more

FDA approves Regeneron's Dupixent in nasal polyps
FDA approved Dupixent dupilumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to treat chronic rhinosinusitis with nasal polyps. Dupixent is the first drug approved for the indication (see "Phase III

Read the full 347 word article

How to gain access

Continue reading with a
two-week free trial.